Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Measurement of Varicella-zoster virus antibody (procedure) |
Component |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody IgG measurement |
Component |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody IgM measurement |
Component |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster immunoglobulin adverse reaction |
Causative agent (attribute) |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Allergy to Varicella-zoster virus antibody (finding) |
Causative agent (attribute) |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
|
Varicella-zoster virus antibody 500 mg powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
|
Product containing precisely Varicella-zoster virus antibody 250 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
|
Varicella-zoster virus antibody-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Anti-varicella-zoster ig injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
|
poudre de 125 UI d'immunoglobuline contre le virus varicella-zoster pour solution injectable en flacon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
|
Allergy to Varicella-zoster virus antibody (finding) |
Causative agent (attribute) |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Immunoglobulin G antibody to Varicellovirus humanalpha3 (substance) |
Is a |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
|
Varicella-zoster antibody level (procedure) |
Component |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicellovirus humanalpha3 IgM |
Is a |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
|
Varicella-zoster virus antibody only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody 104 unit/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody 104 unit/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody 500 mg powder for solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody 500 mg powder for solution for injection vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Varicella-zoster virus antibody 250 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely Varicella-zoster virus antibody 250 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |
Varicella-zoster virus antibody-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Some |
1 |